Skip to main content

Nathan Kaufman Timely Topics Lecture 2020: Programmable Genome Engineering Using CRISPR Technology

Original release date: April 14, 2020 
Access to this course expires on:  March 2, 2023 at 11:59 PM Pacific Time
CME .75

For complimentary access to this item, please enter this promo code at check-out: TT2020

Course Description
Few discoveries transform a discipline overnight, but scientists today can manipulate cells in ways hardly imaginable before, thanks to a peculiar form of adaptive immunity mediated by clustered regularly interspaced short palindromic repeats (CRISPR). From elegant studies that deciphered how these immune systems function in bacteria, researchers quickly uncovered the technological potential of Cas9, an RNA-guided DNA cleaving enzyme, for genome engineering.

Today, this core capability is being harnessed for a wide variety of ambitious applications, including human therapeutics, agricultural improvement, and the elimination of certain infectious diseases. This course discusses the discovery and basic function of CRISPR technology and highlight the different ways this technology is being developed. 

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Understand how research into bacterial immune systems led to the discovery of CRISPR–Cas
  • Comprehend how precise introduction of DNA double-strand breaks acts as a trigger for gene editing applications
  • Learn how CRISPR is being applied to treat human disease, and understand the distinction between somatic and germline gene editing interventions

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Samuel H. Sternberg, PhD

The following planners reported financial relationships:
Ashley Cimino-Mathews: Grant or Research Support: Bristol-Myers Squibb
Yuri Fedoriw: Consultant: Alexion Pharmaceuticals
Joel Greenson:Consultant, Genentech/Roche
Jason Hornick: Consultant: Eli Lilly, Epizyme
Anna Marie Mulligan: Speaker: AstraZeneca; Consultant: Roche
Lynette Sholl: Advisory Board Member: LOXO Oncology; Speaker: AstraZeneca; Grant or Research Support: Roche/Genentech

The following planners reported no relevant financial relationships:
Zubair Baloch, Steven Billings, Daniel Brat, James Cook, Sarah Dry, William Faquin, Karen Fritchie, L. Priya Kunju, Laura Lamps, Rish Pai, David Papke, Jr., Vinita Parkash, Carlos Parra-Herran, Anil Parwani, Rajiv Patel, Deepa Patil, Raja Seethala, Ilan Weinreb, Rhonda Yantiss, Nicholas Zoumberos.

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. View and print your certificate by  clicking here.

Not A Member? Click Here to sign up and receive a discounted rate on all e-Learning courses.